Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
25 mars 2019 07h00 HE
|
Cyclacel
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive...
Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
13 mars 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
07 janv. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
23 oct. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies
04 oct. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J. and HOUSTON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company...
Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
12 sept. 2018 07h00 HE
|
Cyclacel
- Former CMO of Schering-Plough Joins Cyclacel Board - BERKELEY HEIGHTS, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the...
Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference
29 août 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results
09 août 2018 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results
01 août 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results
14 mai 2018 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...